Upon viewing webinar please complete evaluation and then return to the office of Professional & Community Education in order to receive certificate of completion. Completed evaluation may be emailed (CE@mail.wvu.edu), faxed (304.293.5936) or mailed (WVU, PO Box 6830, Morgantown, WV 26506-6830).

Name:_		_	GERIATRICS LUNCHTIME LEAF		
Progra Objectiv		titis C and Baby Boomer	'S Speaker(s)	: Christine Teague, Pharn	nD, MPH, AAHIVP
2. Unde	Review the current epidemiologic trends related to Hepatitis C in the U.S. and in WV. Understand the mechanism of action for the three classes of direct-acting antivirals (DAAs) available for the treatment of chronic hepatitis C.				
	now the two pieces of clinical information that is required to recommend appropriate antiviral regimens for chronic lepatitis C outlined in the IDSA/AASLD chronic hepatitis C management guidelines.				
4. Desc	escribe the most common drug-drug interactions with the DAAs available for the treatment of chronic hepatitis C.				
5. Desc	escribe effective harm-reduction messaging aimed at individuals at risk for, or infected with, chronic Hepatitis C.				
Overa	II Presenta	tion			
1. The Agre		ojectives were met. Somewhat Agree	Disagree	Strongly Disagree	3
2. Briefl	2. Briefly describe what you have learned in this presenation.				
_{3.} Wha	t are some co	mmon drug-drug interactio	ons with the DAAs a	vailable for the treatment of	chronic hepatitis C?
How car	n attending this	program affect your curren	t practice and/or posi	tion?	

What will you do differently in your practice and/or position as a result of your attendance in this program?